6th ICHNO Programme Book

6 TH ICHNO International Conference on innovative approaches in HEAD&NECK ONCOLOGY 16-18 March 2017 Barcelona, Spain

PROGRAMME BOOK AND EXHIBITION GUIDE

5 - 9May 2017 Vienna, Austria

Do not miss the opportunity to access cutting-edge data showcased by world class oncology experts, and to apply the take-home knowledge to your current practice #ESTRO36

WWW.ESTRO.ORG

16-18 March 2017 International Conference on innovative approaches in Head & Neck Oncology Barcelona, Spain

TABLE OF CONTENTS

GENERAL INFORMATION

3

Introduction | 4 Scientific and organising committees | 6 Acknowledgement | 7 Accreditation | 8

General information | 9 Programme overview | 11

SCIENTIFIC PROGRAMME Thursday 16 March 2017 | 14 Friday 17 March 2017 | 18 Saturday 18 March 2017 | 23

13

POSTERS

27

EXHIBITION

41

Floorplan | 42 Company details | 43 Acknowledgement to the industry | 45

SATELLITE SYMPOSIA Thursday 16 March 2017 | 48 Friday 17 March 2017 | 50

47

AUTHORS INDEX

51

2

GENERAL INFORMATION

3

INTRODUCTION

A LETTER OF WELCOME FROM THE CONFERENCE CHAIRPERSONS

The 6th International Conference on innovative approaches in Head and Neck Oncology (ICHNO) will be held from 16 to 18 March 2017 in Barcelona, Spain. The European SocieTy for Radiotherapy and Oncology (ESTRO), the European Head and Neck Society (EHNS) and the European Society of Medical Oncology (ESMO) have the pleasure to welcome you at this conference. This biennial conference will once again provide a unique platform for the dissemination of the most relevant and cutting edge science and innovation in the field of head and neck oncology. This conference has been shaping up to be a major international event in promoting multidisciplinarity in head and neck oncology. With major emphasis on head and neck, this meeting will specifically cover the main following topics: • New insights in the epidemiology and prevention of cancer • Oncogenesis, HPV related cancers, immunology and vaccination • Updated results of practice changing randomised trials • Multidisciplinary management of cancers • Molecular targeted therapies and molecular imaging • Novel radiation and surgical treatments • Towards individualised management of cancer • Robotic and minimally invasive surgery • Reconstructive and salvage surgery • Elderly patients, co-morbidities and their impact on management • New insight in systemic treatments of cancers • Thyroid, nasopharynx cancers and rare cancers • Quality of life, supportive care and management of treatment side effects. The format of the meeting includes prestigious invited ‘state of the art lectures’; lectures on the latest innovative approaches; proffered papers and poster presentations of new data in the field of head and neck oncology. The programme is enriched by a debate and interactive tumour board session where the audience will have the possibility to participate and share their input via an electronic voting system. There is also a special focus on presentations of new data from practice changing randomised trials. Ample time will be given for discussions to allow in-depth interaction among the various disciplines and the participants.

GENERAL INFORMATION | PROGRAMME & EXHIBITION GUIDE

4

To stimulate multidisciplinary interactions among the various specialists, all the lectures, debates, tumour boards and proferred papers are given in the same conference room. We hope that the mix of a rich and challenging scientific programme coupled with the enticing atmosphere of the city of Barcelona will make your attendance worthwhile.

Chairpersons of the 6th ICHNO conference

Jean-Pascal Machiels ESMO

Hans Langendijk ESTRO

C. René Leemans EHNS

PROGRAMME & EXHIBITION GUIDE | GENERAL INFORMATION

5

SCIENTIFIC AND ORGANISING COMMITTEES

SCIENTIFIC COMMITTEE H. Langendijk (NL), Chair C.R. Leemans (NL), Chair J.P. Machiels (BE), Chair R. Brakenhoff (NL) S. Faivre (FR) K. Harrington (UK) P. Nicolai (IT) ADVISORY COMMITTEE FOR RADIATION ONCOLOGY K. Harrington (UK), Chair P. Blanchard (FR) V. Budach (DE)

ADVISORY COMMITTEE FOR SURGERY P. Nicolai (IT), Chair R. de Bree (NL) W. Golusinski (PL) J. Klozar (CZ) J.P. Klussmann (DE) A. Mäkitie (JP) R. Simo (UK) S. Stoeckli (CH) V. Vander Poorten (BE)

ADVISORY COMMITTEE FOR HEAD AND NECK CANCER

J. Giralt (ES) C. Grau (DK) V. Grégoire (BE) D. Raben (US) S. Tribius (DE)

RELATED SCIENCES R. Brakenhoff (NL), Chair J.F. Bakema (NL) J. Hess (DE) K. Hunter (UK)

H. Mehanna (UK) M. Robinson (UK) J.P. Machiels (BE) N. Stoecklein (DE)

ADVISORY COMMITTEE FOR MEDICAL ONCOLOGY S. Faivre (FR), Chair E. Cohen (US) U. Keilholz (DE) C. Le Tourneau (FR)

L. Licitra (IT) P. Szturz (CZ) M. Tahara (JP) J. Vermorken (BE)

GENERAL INFORMATION | PROGRAMME & EXHIBITION GUIDE

6

ACKNOWLEDGEMENT

ESTRO, the European SocieTy for Radiotherapy and Oncology, EHNS, the European Head and Neck Society, And ESMO, the European Society for Medical Oncology,

Wish to thank the Scientific Committee Chairs, Hans Langendijk, C. René Leemans and Jean-Pascal Machiels for having accepted the responsibility to develop the scientific programme of this conference. A special thank you to the members of the advisory committees for having supported the development of the programme.

PROGRAMME & EXHIBITION GUIDE | GENERAL INFORMATION

7

ACCREDITATION

The 6th ICHNO conference is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 6th ICHNO conference is designated for a maximum of (or ‘for up to’) 15 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/ internationalcme. Live educational activities, occurring outside of Canada, recognised by the UEMS- EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

6th ICHNO Conference is accredited with 16 Category 1 ESMO MORA Points.

GENERAL INFORMATION | PROGRAMME & EXHIBITION GUIDE

8

GENERAL INFORMATION

VENUE Fira Barcelona Avda. Reina Maria Cristina 08004 Barcelona Spain

EXHIBITION An exhibition featuring radiotherapy equipment and pharmaceutical companies as well as medical publishers will be held in the exhibition area. The exhibition will be open during the following times: Thursday 16 March as from 09:30 to 20:00 Friday 17 March from 09:30 to 17:00 Saturday 18 March from 09:30 to 11:00. INSURANCE The organiser does not accept liability for individual medical, travel or personal insurance. Participants are strongly advised to take out their own personal insurance policies. In case an unforeseen event would force ESTRO to cancel the meeting, the Society will reimburse the participants the registration fee minus 15% for handling charges. ESTRO will not be responsible for the refund of travel and accommodation costs. LUNCHEONS AND REFRESHMENTS The registration fee for the conference includes lunches and coffee breaks served in the exhibition area. Entrance is free for all the registered participants.

ACCOMMODATION The official housing agent for the

conference will be Kuoni Congress and they will operate an accommodation desk in the registration area on:

Thursday 16 March: 09:00 – 16:30 Friday 17 March: 09:00 – 16:30 Saturday 18 March: 09:00 – 13:00

CERTIFICATES Certificates of attendance will be issued as of Friday 17 March in the afternoon through the designated stations in the registration area.

CURRENCY The currency in Spain is the EURO.

OFFICIAL LANGUAGE The official language of the meeting is English. No simultaneous translation will be provided. POSTERS The poster area will be in the exhibition hall and therefore, posters may be viewed at any time during conference hours.

PROGRAMME & EXHIBITION GUIDE | GENERAL INFORMATION

9

NETWORKING EVENING All participants and company delegates are invited to the networking evening on Thursday 16 March 2017 from 19:00 to 20:00. The networking evening will take place in the exhibition area.

Buses are adapted for persons with reduced mobility (PRM). They dispose over a wide space especially designed for your luggage. Free wifi and USB chargers on board. Price single ticket: € 5,9. METRO The subway (or metro) now connects both terminals of the Airport with Barcelona underground network. The line is called L9 Sud. There are stops at T1 (inside the building) and T2 (outside the building, next to train station), in both cases follow the signs. The L9 Sud runs directly from Barcelona Airport to the South Entrance at Fira Gran Via. TRAIN You can catch the train from Clot, Passeig de Gracia, or Barcelona Sants (Sants Estacio). The name of the stop you want for the airport is Aeropuerto. If travelling from the airport to the city centre you can get off at Barcelona Sants, Passeig de Gracia or Clot which are serviced by metro stops. From these you can change for the Barcelona metro underground system to go to your final destination.

WIFI Wifi will be available in the whole congress centre

TRAVEL INFORMATION How to reach Barcelona from the airport: TAXI El Prat International Airport is approxi- mately 14 kilometres south-west of the centre of Barcelona and taxis are available at the airport 24 hours a day. It takes roughly between twenty and forty minutes into the centre of town and the fare is about € 30-45; tariffs can vary according to the time of day and supplements (eg luggage). The fares should be displayed in the taxi and the amount payable should be indicated on the meter. AEROBUS AEROBÚS is the official shuttle bus service that connects the airport BCN- El Prat and the centre of Barcelona every 5 minutes, every day of the year, in approximately 35 minutes. This is the fastest way to reach the city centre with public transport. Passengers are able to travel between any of the two airport terminals (T1 or T2) and the centre of Barcelona (Pl. Catalunya) in only three stops in a fast, comfortable and economical way. Along the route there are stops at the most important points of the city: Pl. Catalunya, Sepúlveda-Urgell, Pl. Espanya, Gran Vía- Urgell, and Pl. Universitat.

GENERAL INFORMATION | PROGRAMME & EXHIBITION GUIDE

10

PROGRAMME OVERVIEW

Thursday 16 March 2017 09:00-09:15 Opening remarks 09:15-09:45 Keynote lecture 1: Immunotherapy for head and neck cancer: integrating the fourth modality 09:45-10:15 Keynote lecture 2: State of the art in robotic surgery 10:15-10:45 Coffee break 10:45-12:00 Symposium 1: Prognostic modelling 12:00-13:00 Proffered papers 1

13:00-14:30 Lunch and Satellite symposium 14:30-16:00 New data from randomised trials 16:00-16:30 Coffee break 16:30-17:45 Symposium 2: Reductions of radiation induced toxicities

17:55-18:55 Satellite symposium 19:00-20:00 Networking evening

Friday 17 March 2017 09:00-09:30 Keynote lecture 3: New imaging techniques 09:30-10:00 Keynote lecture 4: HNC biomarkers - how do we translate biology into useful assays for clinical care? 10:00-10:30 Coffee break 10:30-11:30 Proffered papers 2 11:30-12:45 Symposium 3: New developments in surgery 12:45-14:15 Lunch and Satellite symposium 14:15-15:15 Interactive tumour board session: Limited T4a larynx cancer 15:15-16:00 Poster discussion 16:00-16:30 Coffee break 16:30-17:45 Symposium 4: New developments in systemic treatment Saturday 18 March 2017 08:45-09:15 Keynote lecture 5: Clinical implementation of adaptive radiotherapy: challenges ahead 09:15-10:30 Symposium 5: Adenoid cystic carcinoma 10:30-11:00 Coffee break 11:00-12:00 Proffered papers 3 12:00-13:00 Debate 1: Early stage HPV related oropharyngeal cancer should not be treated with radiotherapy anymore 13:00-13:15 Concluding remarks

PROGRAMME & EXHIBITION GUIDE | GENERAL INFORMATION

11

ESTRO and Elsevier proudly announce three new open access journals in the field of radiation oncology to accompany the premier journal in the field, Radiotherapy & Oncology. ESTRO’s family of journals further the Society’s mission to foster the role of radiation oncology to improve the care of patients with cancer. A Family of Radiation Oncology Journals from ESTRO

Clinical and Translational Radiation Oncology – ctRO All aspects of clinical and translational radiation oncology research, particularly new developments in radiobiology, clinical interventions and treatments, data sciences, epidemiology, and oncopolicy. Editors-in-Chief:

Pierre Blanchard, Villejuif, France Daniel Zips, Tübingen, Germany

Physics and Imaging in Radiation Oncology – phiRO Medical physics and imaging in radiation oncology. Editors-in-Chief:

Lorenzo Bonomo, Rome Italy Ludvig Muren, Aarhus, Denmark

Technical Innovations and Patient Support in Radiation Oncology – tipsRO Technology and patient care, including treatment planning, workflows and delivery; treatment verification; supportive care; psycho-oncology; patient reported outcome measures; risk management; radiotherapy quality management and control; and personalisation. Editors-in-Chief: Sara Faithfull, Guildford, UK Michelle Leech, Dublin, Ireland

Read volume 1 and submit your own work www.ctro.science • www.phiro.science • www.tipsro.science

SCIENTIFIC PROGRAMME

13

THURSDAY 16 MARCH 2017

Conference remarks Opening remarks 09:00 - 09:15 | Auditorium

09:00 Chair: H. Langendijk (The Netherlands) 09:05 Chair: C.R. Leemans (The Netherlands) 09:10 Chair: J.P. Machiels (Belgium)

Keynote lecture Immunotherapy for head and neck cancer: integrating the fourth modality 09:15 - 09:45 | Auditorium Chair: H. Langendijk (The Netherlands) Chair: C.R. Leemans (The Netherlands) Chair: J.P. Machiels (Belgium) 09:15 Immunotherapy for head and neck cancer: integrating the fourth modality Speaker: R. Ferris (USA)

SP-001

Keynote lecture State of the art in robotic surgery 09:45 - 10:15 | Auditorium Chair: H. Langendijk (The Netherlands) Chair: C.R. Leemans (The Netherlands) Chair: J.P. Machiels (Belgium) 09:45 State of the art in robotic surgery Speaker: E. Moore (USA)

SP-002

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

14

Symposium Prognostic modelling 10:45 - 12:00 | Auditorium Chair: R. Brakenhoff (The Netherlands) Chair: J.P. Klussmann (Germany) 10:45 Radiomics: the poor man molecular imaging? Speaker: P. Lambin (The Netherlands)

SP-003

11:10 Novel insights into head and neck cancer by transcriptome approaches Speaker: L. De Cecco (Italy)

SP-004

11:35 The TRIPOD guideline

Speaker: K.G.M. Moons (The Netherlands)

SP-005

Proffered papers Proffered papers 1

12:00 - 13:00 | Auditorium Chair: M. Merlano (Italy)

12:00 Outcomes of head and neck cancer with N3 Nodal Disease: A review of the National Cancer Data Base H.C. Ko (USA), S. Chen, A. Wieland, M. Yu, A. Baschnagel, J. Brower, T. McCulloch, G. Hartig, P. Harari, M. Witek 12:10 Sentinel node biopsy for early stage oral cancer; experience of 2 Dutch head and neck centers I. Den Toom (The Netherlands), L. Janssen, R. Van Es, O. Hoekstra,

OC-006

H. Karagozoglu, B. De Keizer, A. Van Schie, S. Willems, S. Van Weert, R. Leemans, E. Bloemena, R. De Bree

OC-007

12:20 Incidence of malignant disease outside the head and neck region in head and neck cancer M. Bernsdorf (Denmark), A. Loft, A. Berthelsen, L. Specht, J. Kjems, A. Gothelf, C. Kristensen, J. Friborg

OC-008

PROGRAMME & EXHIBITION GUIDE | SCIENTIFIC PROGRAMME

15

12:30 Validation of a prognostic model in 600 patients with squamous cell carcinoma J.H. Rasmussen (Denmark), H. Katrin, I.R. Vogelius, J. Friborg, B.M. Fischer, L. Specht

OC-009

12:40 Discussant: J. Guigay (France)

Randomised trials New data from randomised trials 14:30 - 16:00 | Auditorium Chair: J. Vermorken (Belgium) 14:30 Update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC) Speaker: P. Blanchard (USA)

SP-010

14:45 Discussant: L. Licitra (Italy) 14:52 Update of the PET NECK trial Speaker: H. Mehanna (UK) 15:07 Discussant: W. Budach (Germany) 15:14 Update of neck dissection trial Speaker: A. D’Cruz (India) 15:29 Discussant: R. De Bree (The Netherlands) 15:36 Update on the ARCON study Speaker: J. Kaanders (The Netherlands)

SP-011

SP-012

SP-013

15:51 Discussant: S. Nuyts (Belgium)

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

16

Symposium Reductions of radiation induced toxicities 16:30 - 17:45 | Auditorium Chair: W. Budach (Germany) Chair: J. Giralt (Spain) 16:30 Target volume reduction Speaker: W. De Neve (Belgium)

SP-014

16:55 Prophylactic swallowing exercises in head and neck radiotherapy Speaker: H.R. Mortensen (Denmark) 17:20 The value of proton therapy for head and neck malignancies: reducing side effects and improving outcomes Speaker: P. Blanchard (USA)

SP-015

SP-016

PROGRAMME & EXHIBITION GUIDE | SCIENTIFIC PROGRAMME

17

FRIDAY 17 MARCH 2017

Keynote lecture New imaging techniques 09:00 - 09:30 | Auditorium

Chair: L. Licitra (Italy) Chair: M. Quer (Spain) 09:00 New imaging techniques Speaker: R. Maroldi (Italy)

SP-017

Keynote lecture HNC Biomarkers - how do we translate biology into useful assays for clinical care? 09:30 - 10:00 | Auditorium Chair: L. Licitra (Italy) Chair: M. Quer (Spain) 09:30 HNC Biomarkers - how do we translate biology into useful assays for clinical care? Speaker: T. Seiwert (USA) Proffered papers Proffered papers 2 10:30 - 11:30 | Auditorium Chair: P. Szturz (Czech Republic) 10:30 The phase III study INTERCEPTOR: preliminary results N. Denaro (Italy), S. Vecchio, A. Bagicalupo, E. Russi, M. Rampino, M. Benasso, G. Numico, L. Licitra, O. Ostellino, M. D’amico, P. Curcio, M. Merlano 10:40 Sarcopenia predicts chemotherapy dose-limiting toxicity in patients with head and neck cancer S.I. Bril (The Netherlands), A.W. Wendrich, J.E. Swartz, I. Wegner, A. De Graeff, E.J. Smid, R. De Bree, A.J. Pothen

SP-018

OC-019

OC-020

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

18

10:50 Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN D. Soulières (Canada), S. Faivre, R. Mesía, E. Remenár, S.H. Li, A. Karpenko, A. Dechaphunkul, U. Keilholz, L. Kiss, J.C. Lin, R. Nagarkar, L. Tamás, S.B. Kim, J. Erfán, A. Alyasova, A. Yovine, S. Le Mouhaër, N. Solovieff, S. Turri, L. Licitra 11:00 Association of patient derived xenograft formation with oral cavity squamous cell cancer outcomes A. Hope (Canada), C. Karamboulas, W. Xu, S. Huang, J. Kim, S. Bratman, J. Cho, J. Ringash, M. Giuliani, A. Bayley, J. Waldron, B. Perez-Ordonez, D. Goldstein, J. De Almeida, D. Brown, J. Irish, P. Gullane, R. Gilbert, B. O’Sullivan, L. Ailles Symposium New developments in surgery 11:30 - 12:45 | Auditorium Chair: P. Nicolai (Italy) Chair: K. Harrington (UK) 11:30 New developments in sentinel node biopsy of head and neck cancer Speaker: S. Stoeckli (Switzerland) 11:10 Discussant: J. Vermorken (Belgium)

OC-021

OC-022

SP-023

11:55 Integrated 3D virtual visualisation of pathology and reconstructive planning in head and neck cancer Speaker: M. Witjes (The Netherlands)

SP-024

12:20 Oropharyngeal surgery Speaker: T. Jones (UK)

SP-025

PROGRAMME & EXHIBITION GUIDE | SCIENTIFIC PROGRAMME

19

Interactive tumour board session Limited T4a larynx cancer 14:15 - 15:15 | Auditorium Chair: H.E. Eckel (Austria) Panellists: A. Castro (Portugal)

J.G. Eriksen (Denmark) W. Golusinski (Poland) A. Argiris (Greece) S. Tribius (Germany) D. Chevalier (France)

Poster discussion Poster discussion 15:15 - 16:00 | Auditorium Chair: C. Simon (Switzerland)

Correlation and prognostic impact of HPV and p16 on RT- outcome in larynx and hypopharynx cancer P. Lassen (Denmark), M. Schou, J. Overgaard, J. Alsner cfHPV DNA as a marker of treatment results in patients with HPV-related head and neck cancer T. Rutkowski (Poland), A. Mazurek, M. Snietura, A. Wygoda, M. Kentnowski, P. Polanowski, U. Dworzecka, B. Pilecki, K. Dębiec, I. Gawron, J. Niedziałek, W. Pigłowski, U. Bojko, P. Widłak, K. Składowski Prognostic and predictive impact of HPV status in oropharyngeal cancer: the MARCH-HPV project B. Lacas (France), P. Lassen, A. Trotti, B. Zackrisson, Q. Zhang, J.P. Pignon, J. Overgaard, P. Blanchard

PD-026

PD-027

PD-028

15:15 Discussant: J. Hess (Germany)

Causes-of-death underestimate the burden of head and neck cancers in France (EPICORL study) Y. Pointreau (France), L. Sagaon Teyssier, L. Geoffrois, M. Bec,

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

20

C. Godard, C. Even, L. Lévy-Bachelot, F. Huguet, S. Témam, M. Schwarzinger Survival of patients with head and neck cancers in France (EPICORL study) F. Huguet (France), L. Geoffrois, B. Le Vu, Y. Pointreau, M. Bec, C. Even, L. Lévy-Bachelot, S. Temam, M. Schwarzinger Quality of life, health status and work in head and neck cancer survivors treated with radiotherapy A. Matías-Pérez (Spain), B. G. Díaz de Tudanca, G. Gallego-Herreros, M. Sánchez-Barba, P. Soria-Carreras, A. Nieto-Palacios, A. Rodríguez-Gutierrez, L.A. Pérez-Romasanta Pharyngeal constrictor muscle dose correlated with dysphagia after radiotherapy in head and neck J. Miroir (France), J. Biau, N. Saroul, C. Millardet, M. Lapeyre Cetuximab + RT shows an excellent long term OS in patients with both high ADCC and high EGFR M. Merlano (Italy), L. Lattanzio, N. Denaro, D. Vivenza, G. Milano, R. Vigna Taglianti, A. Merlotti, M. Ferrero, C. Lo Nigro Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer E. Orlandi (Italy), G. Infante, R. Granata, N. Iacovelli, R. Miceli, A. Cavallo, S. Alfieri, C. Bergamini, C. Resteghini, D. Galbiati, L. Locati, S. Tana, S. Naimo, C. Fallai, L. Licitra, P. Bossi

PD-029

PD-030

PD-031

15:30 Discussant: A. Mäkitie (Finland)

PD-032

PD-033

PD-034

15:45 Discussant: D. Raben (USA)

PROGRAMME & EXHIBITION GUIDE | SCIENTIFIC PROGRAMME

21

Symposium New developments in systemic treatment 16:30 - 17:45 | Auditorium Chair: J.E. Bakema (The Netherlands) Chair: J. Vermorken (Belgium) 16:30 Is there still a role for targeted signaling agents in head and neck cancer? Speaker: C. Le Tourneau (France) 16:55 Immunity and immune toxicity: clinical management of immune checkpoint inhibition Speaker: U. Keilholz (Germany)

SP-035

SP-036

17:20 Immunotherapy beyond anti PD1 inhibitors Speaker: P. Coulie (Belgium)

SP-037

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

22

SATURDAY 18 MARCH 2017

Keynote lecture Clinical implementation of adaptive radiotherapy: challenges ahead 08:45 - 09:15 | Auditorium Chair: V. Budach (Germany) Chair: A. Mäkitie (Finland) 08:45 Clinical implementation of adaptive radiotherapy: challenges ahead Speaker: O. Hamming-Vrieze (The Netherlands) Symposium Adenoid cystic carcinoma 09:15 - 10:30 | Auditorium Chair: R. De Bree (The Netherlands) Chair: S. Faivre (France) 09:15 Adenoid cystic carcinoma: considerations in surgical approach and factors modifying expected outcome following treatment Speaker: V. Vander Poorten (Belgium) 09:40 Radiotherapy in adenoid cystic carcinoma (ACC) of the head and neck Speaker: A. Jensen (Germany) Proffered papers Proffered papers 3 11:00 - 12:00 | Auditorium Chair: V. Vander Poorten (Belgium) 11:00 Re-irradiation with curative intent of squamous cell carcinomas of the head and neck in Denmark B.E. Engelmann (Denmark), M. Andersen, C. Elmann, M. Farhadi, A. Gothelf, C.R. Hansen, K. Nowicka-Matus, J.B.B. Petersen, E. Samsøe, H.M. Sand, B. Smulders, J. Johansen 10:05 When to treat and how to treat distant metastases Speaker: P. Bossi (Italy)

SP-038

SP-039

SP-040

SP-041

OC-042

PROGRAMME & EXHIBITION GUIDE | SCIENTIFIC PROGRAMME

23

11:10 Re-irradiation in head and neck cancers: A single institution prospective cohort study R. Salunkhe (India), S. Ghosh Laskar, S. Chakraborty, T. Gupta, A. Budrukkar, V. Murthy, J.P. Agarwal 11:20 ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer M. Beasley (UK), C. Nutting, J. Morden, D. Bernstein, V. Cosgrove, S. Fisher, B. Foran, T. Guerrero-Urbano, D. Gujral, K. Harrington, E. Junor, H. Mehanna, A. Miah, N. Palaniappan, S. Ramkumar, P. Sanghera, M. Sen, A. Sibtain, W. Soe, C. West, D. Piercey, S. Witts, M. Emson, E. Hall 11:30 Recurrence patterns after 40 Gy to the elective treated neck in head and neck cancer. D. Nevens (Belgium), F. Duprez, J. Daisne, J. Schatteman, W. De Neve, S. Nuyts

OC-043

OC-044

OC-045

11:40 Discussant: C. Grau (Denmark)

Debate Early stage HPV related oropharyngeal cancer should not be treated with radiotherapy anymore

12:00 - 13:00 | Auditorium Chair: V. Grégoire (Belgium) Chair: R. Simo (UK) 12:00 For the motion

Speaker: C. Simon (Switzerland)

SP-046

12:15 Against the motion

Speaker: V. Budach (Germany)

SP-047

12:30 For the motion

Speaker: J. Klozar (Czech Republic)

SP-048

12:38 Against the motion

Speaker: J. Giralt (Spain)

SP-049

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

24

Conference remarks Concluding remarks 13:00 - 13:15 | Auditorium

13:00 H. Langendijk (The Netherlands) 13:05 C.R. Leemans (The Netherlands) 13:10 J.P. Machiels (Belgium)

PROGRAMME & EXHIBITION GUIDE | SCIENTIFIC PROGRAMME

25

SCIENTIFIC PROGRAMME | PROGRAMME & EXHIBITION GUIDE

26

POSTERS

27

Poster Multidisciplinary management

The interplay between all-trans-retinoic acid and radiotherapy in inducing cancer stem cell arrest L.G. Marcu (Romania), D. Marcu A 7-year overview on advanced nasopharynx’s cancer: features influencing survival outcomes A. Nogueira (Portugal), M. Teixeira, L. Khouri, F. Branquinho, P. Jacinto N2 node metastasis in squamous cancers of head and neck: failure patterns and future management S. Giri (USA), M.R. Kanakamedala, S. Vijayakumar, S. Mangana, E.L. Bhanat, M.P. Giri, M. Chhabria Impact of PTV coverage on local recurrences and overall survival after IMRT for head and neck cancers L. Piram (France), T. Frederic-Moreau, J. Miroir, N. Saroul, N. Pham-Dang, L. Berger, J. Biau, M. Lapeyre Cisplatin use in UK head and neck cancer management: a clinician survey of current practice B. Foran (UK), J. Fenwick, B. Byrne, J. Christian Subglottic squamous cell carcinoma in Denmark from 1971-2016 – a report from the DAHANCA-group L. Hill-Madsen (Denmark), C.A. Kristensen, E. Andersen, J. Johansen, L.J. Andersen, H. Primdahl, J. Overgaard, N.M. Lyhne Tolerance and outcomes of radical hypofractionated radiotherapy for glottic cancer in the elderly A. Zeniou, S. Ramasamy (UK), L. Murray, M. Sen, K. Cardale, K. Dyker, R. Prestwich Radiation induced skin reaction in head neck malignancies and assessment of quality of life V. Pareek (India), M. Chandra, R. Bhalavat

PO-050

PO-051

PO-052

PO-053

PO-054

PO-055

PO-056

PO-057

POSTERS | PROGRAMME & EXHIBITION GUIDE

28

Nasopharingeal carcinoma treated with intensity modulated radiotherapy in an non–endemic area. A. Lozano (Spain), A. Navarro, H. Letelier, S. Vazquez, V. Navarro, J. Nogues, R. Mesia Efficacy and safety of modified-increased FEP regimen and chemo- radiation for locally advanced HNSCC A. Ouhajjou (Morocco), Z. Fadoukhair, H. Faouzi Dose received by the pituitary gland during irradiation of nasopharyngeal carcinoma N. Sellami (Tunisia), W. Siala, H. Daoud, W. Mnejja, T. Sahnoun, L. Farhat, J. Daoud Stomal underdose in post-laryngectomy radiotherapy via VMAT: phantom study and clinical case analysis S. Lee (USA), J. Zhang, B.K. Lee, J. Cho-Lim, W.S. Inouye, W.C. Lorentz, M.Y. Leu Retrospective analysis of 72 patients treated with FEP regimen and CCRT for locally advanced NPC A. Ouhajjou (Morocco), Z. Fadoukhair, H. Faouzi Waiting time and fast track model for head and neck cancer patients in Finland H. Irjala (Finland), E. Halme, A. Makitie, T. Atula, P. Koivunen Normal tissue complication probability model for tube feeding dependence 6 months after radiotherapy N. Kanayama (Japan), R.G.J. Kierkels, R.J.H.M. Steenbakkers, A. Van der Schaaf, M. Miyazaki, T. Fujii, K. Nishiyama, J.A. Langendijk, T. Teshima Survival outcomes in unknown primary with nodal metastases and role of radiation therapy A. Srivastava (India), R. Bhalavat, M. Chandra, V. Pareek Early-stage tonsil cancer submitted to primary surgery and adjuvant therapy: retrospective study C. Pedro (Portugal), E. Netto, R. Pocinho, A. Mota, P. Pereira, M. Magalhães, P. Montalvão, F. Santos

PO-058

PO-059

PO-060

PO-061

PO-062

PO-063

PO-064

PO-065

PO-066

PROGRAMME & EXHIBITION GUIDE | POSTERS

29

Mucosal Melanoma of the head and neck: single institution experience C. Viveiros (Portugal), E. Netto, A. Mota, R. Pocinho, M. Fortunato, P. Montalvão, M. Magalhães, F. Santos Head and neck cancer of unknown primary origin: a single institution experience N. Ferreira (Portugal), J. Silva, E. Netto, G. Marau, M. Ferreira, F. Santos Radiation dose and distribution following transoral robotic surgery of the palatine tonsil S . Naqvi (USA), J. Ferrell, A. Blanco, J. Bigcas, K. Jain, R. Karni Conventional vs bifractionated radiotherapy innasopharyngeal cancer 10 years followup of phase 3 trial W. Siala (Tunisia), N. Sellami, N. Toumi, M. Drira, A. Ghorbel, M. Frikha, J. Daoud Dose to the thyroid gland during irradiation of nasopharyngeal carcinoma W. Siala (Tunisia), N. Sellami, H. Daoud, M. Kallel, W. Mnejja, L. Farhat, J. Daoud Compliance and acute toxicity of chemoradiotherapy for undifferentiated nasopharyngeal cancer N. Jovanovic Korda (Serbia), T. Ursulovic, S. Vucicevic, V. Vujanac, M. Kreacic Viable tumour in salvage neck dissections: relation with initial treatment, lymph node size and HPV K. Van den Bovenkamp (The Netherlands), B. Dorgelo, M.G. Noordhuis, B.F.A.M. Van der Laan, B. Van der Vegt, H.P. Bijl, J.L. Roodenburg, B.A.C. Van Dijk, G.B. Halmos, E.M.D. Schuuring, J.A. Langendijk, S.F. Oosting, B.E.C. Plaat Concomitant chemoradiotherapy alone or with induction chemotherapy in advanced head and neck cancer R. Teixeira, A. Cavaleiro, P. Vieira, F. Aveiro, G. Vieira (Portugal) Treatment of nasopharyngeal cancer: a Serbian institututinal experience T. Ursulovic (Serbia), N. Babovic

PO-067

PO-068

PO-069

PO-070

PO-071

PO-072

PO-073

PO-074

PO-075

POSTERS | PROGRAMME & EXHIBITION GUIDE

30

Predictive and prognostic value of pretreatment FDG-PET SUV parameters in head and neck L. Deantonio (Italy), M. Paolini, E. Puta, E. Ferrara, L. Vigna, R. Matheoud, G. Sacchetti, M. Brambilla, M. Krengli Cisplatin or Carboplatin in locally advanced head and neck squamous cell carcinoma Abstract withdrawn

PO-076

PO-077

Poster Innovative treatments

The evaluation of the set-up differences between radiation therapists for head and neck patients E. Kara (Turkey), A. Yazici, B. Dirican, B. Boybas, M.A. Gunaydin, A. Kartal, M. Akmansu, A. Hicsonmez Hypofractionated versus prolonged chemo-IMRT schedules in oropharyngeal carcinoma I. Boon (UK), C. Boon, P. Nightingale, J. Cashmore, G. Sangha, M. Hickman, H. Benghiat, C. Fong, P. Sanghera, A. Hartley Challenges and opportunities in head and neck cancer research in the UK: a survey of oncologists B. Foran (UK), J. Fenwick, B. Byrne, J. Christian Recurrence analysis in head and neck squamous cell carcinoma treated with adjuvant EUD-based IMRT S. Welz (Germany), T. Schönle, D. Thorwarth, D. Zips Correlation between HI, GI, CI and size of metastases for linac-based high dose SRT / SRS B. Tas (Turkey), I.F. Durmus, A. Okumus, O.E. Uzel Adaptative radiotherapy for nasopharyngeal carcinoma L. Farhat (Tunisia), W. Mnejja, T. Sahnoun, F. Dhouib, J. Daoud HDR interstitial brachytherapy for head and neck malignancies with Iridium 192 implants V. Pareek (India), R. Bhalavat, M. Chandra

PO-078

PO-079

PO-080

PO-081

PO-082

PO-083

PO-084

PROGRAMME & EXHIBITION GUIDE | POSTERS

31

Role of L glutamine in reducing severity of chemoradiation induced mucositis and improve QoL in HNC V. Pareek (India), R. Bhalavat, M. Chandra Brachial plexus position reproducibility for head and neck radiotherapy and its dosimetric impact S. English (UK), A. Thompson Adaptive 18F-FDG-PET-guided reirradiation for recurrent and second primary head and neck cancer J. Schatteman (Belgium), D. Van Gestel, D. Berwouts, W. De Gersem, I. Goethals, L. Olteanu, S. Rottey, T. Vercauteren, W. De Neve, F. Duprez The study of constant dose rate and gantry speed arc therapy for glottic carcinoma on Varian 23EX R. Zhang, Y. Gao, W. Bai (China), M. Miao, D. Liu Melatonin enhances the toxicity of radio- and chemotherapy in head and neck cancer cells G. Escames (Spain), B.I. Fernández-Gil, A. Guerra-Librero, Y. Shen, S. García-López, J. Florido, R. Sayed, D. Acuña-Castroviejo, J. Esposito Oncostatic effect of melatonin in head and neck cancer: role of mitochondrial function G. Escames (Spain), A. Guerra-Librero, Y. Shen, J. Florido, R. Sayed, M. Molina-Navarro, M. Gonzalez-Diez, D. Acuña-Castroviejo, J. Exposito Intensity modulated radiotherapy (IMRT) in nasopharyngeal cancer – a dosimetric and QoL analysis V. Pareek (India), R. Bhalavat, M. Chandra Dosimetric comparaison of conformal and intensity modulated radiotherapy for locally recurrent NPC W. Mnejja (Tunisia), L. Farhat, H. Daoud, T. Sahnoun, N. Fourati, W. Siala, J. Daoud COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients C. Nutting, J. Morden, M. Beasley, S. Bhide (UK), M. Emson, M. Evans, L. Fresco, D. Gujral, K. Harrington, C. Lemon, R. Neupane, K. Newbold, R. Prestwich, M. Robinson, P. Sanghera, M. Sivaramalingam, M. Sydenham, E. Wells, S. Witts, E. Hall

PO-085

PO-086

PO-087

PO-088

PO-089

PO-090

PO-091

PO-092

PO-093

POSTERS | PROGRAMME & EXHIBITION GUIDE

32

Radiation induced volume changes in salivary glands in head and neck cancer patients receiving IMRT D. Borade (India), M. Chandra, R. Bhalavat, L. Nellore, K. George, K. Kalariya, V. Pareek, Z. Moosa, N. Reddy, A. Shrivastava Electrochemotherapy for mucosal head and neck tumours: results from a phase II clinical trial. C.C. Plaschke (Denmark), J. Gehl, H. Johannesen, H. Hendel, K. Kiss, R. Hansen, I. Wessel Dosimetric evalutation of volumetric modulated arc therapy (VMAT) in sinonasal cancer raiotherapy E. Donini (Italy), S. Magi, S. Ricci, E. Pasquini, G. Frezza Droplet digital PCR for detection of circulating tumour DNA in blood of head and neck cancer patients J.H. Van Ginkel (The Netherlands), M.M.H. Huibers, R.J.J. Van Es, R. De Bree, S.M. Willems Searching for therapeutic targets from whole transcriptome of oral cancer B. Roy (India), N. De Sarkar, R. Singh Human papillomavirus in head and neck cancer in the UK: a clinician survey of current practice B. Foran (UK), J. Fenwick, B. Byrne, J. Christian Oral cancer microenvironment - PI3K/AKT/mTOR and ERK/MAPK pathways dependent targets C. Domingues (Portugal), M. Laranjo, A.M. Abrantes, A.B. Sarmento-Ribeiro, L. Carvalho, M.F. Botelho, H. Silva, M. Dourado Osteopontin (OPN) as an instant, predictive marker of tumour hypoxia in head and neck cancer patients J. Mrochem-Kwarciak (Poland), T. Rutkowski, A. Wygoda, R. Deja, A. Hajduk, Ł. Boguszewicz, P. Widłak, K. Składowski Poster Biology, HPV and molecular targeting

PO-094

PO-095

PO-096

PO-097

PO-098

PO-099

PO-100

PO-101

PROGRAMME & EXHIBITION GUIDE | POSTERS

33

EGFR detection in saliva as an easy diagnostic and prognostic tool in oral squamous cell cancer C. Piazza (Italy), A. Paderno, L. Zanotti, E. Bandiera, F. Del Bon, C. Romani, P. Perotti, E. Bignotti, N. Montalto, R. Morello, F.E. Odicino, P. Nicolai, A. Ravaggi Oropharyngeal cancer patient-derived xenografts: characterisation and radiosensitivity. J. Lilja-Fischer (Denmark), B. Ulhøi, J. Alsner, P. Lassen, V. Nielsen, J. Overgaard Everolimus in oral cancer: a potential therapeutic approach dependent on cell type? C. Domingues (Portugal), P. Matafome, S. Neves, M. Laranjo, R. Seiça, M.F. Botelho, A.B. Sarmento-Ribeiro, M. Dourado Is there justification for age bias in HPV p16 testing for oropharyngeal squamous cell carcinoma? S. McCauley (UK), P. McCloskey, C. Lyons, K. Brown, K. Rooney, F. Houghton Prognostic significance of cyclin D1 and pRb expression in oropharyngeal carcinoma M.A. Broglie (Switzerland), M.M. Plath, S.J. Stoeckli, W. Jochum Clinical outcomes of HPV-positive non-oropharyngeal squamous cell carcinoma: analysis of the NCDB H. Ko (USA), R. Sacotte, M. Yu, S. Chen, A. Wieland, M. Witek TLR induced PDL-1 expression in HNSCC as a potential tool of immunomodulation B. Wollenberg (Germany), R. Pries, M. Drenckhahn, K. Ploetze-Martin, B. Wollmann

PO-102

PO-103

PO-104

PO-105

PO-106

PO-107

PO-108

POSTERS | PROGRAMME & EXHIBITION GUIDE

34

Poster Imaging and radiomics

The added value of SPECT-CT for identification of sentinel lymph nodes in early stage oral cancer I. Den Toom (The Netherlands), A. Van Schie, S. Van Weert, O. Hoekstra, H. Karagozoglu, E. Bloemena, R. De Bree Analysis of loco-regional failures after IMRT for HNSCC using deformable image registration R. Zukauskaite (Denmark), C.R. Hansen, J. Johansen, C. Grau, J. Overgaard, C. Brink Dermal backflow: NIRFLI pattern associated multimodality therapy in patients with oropharynx cancer S. Naqvi (USA), I. Tan, J. Rasmussen, M. Aldrich, J. Morrow, A. Blanco, C. Gutierrez, K. Jain, E. Sevick-Muraca, R. Karni Role for interim PET in patient selection for dose escalation and boost volume definition in HNSCC J. Lynch (UK), A. Nisbet, C. Clark, S. Whitaker, K. Wood Dynamics of biological imaging parameters in PW-MRI and FMISO-PET/ CT during chemoradiation of SCCHN A. Bunea, H. Bunea (Germany), C. Stoykow, L. Majerus, N. Wiedenmann, M. Mix, P. Meyer, M. Bock, A.L. Grosu Alterations in tumour hypoxia in serial F-MISO/PET-CT during chemoradiation in HNSCC H. Bunea, A. Bunea (Germany), L. Majerus, C. Stoykow, M. Mix, A.L. Grosu A [18F]FDG-PET adaptive thresholding algorithm delineation of RT tumour volumes of head and neck cancer L. Deantonio (Italy), M. Paolini, L. Vigna, G. Loi, L. Masini, G. Sacchetti, R. Matheoud, M. Brambilla, M. Krengli Potential applications of spectral CT imaging in patients with head and neck squamous cell carcinoma B. Peltenburg (The Netherlands), J.W. Dankbaar, M.J. Willemink, R. De Bree, T. Leiner

PO-109

PO-110

PO-111

PO-112

PO-113

PO-114

PO-115

PO-116

PROGRAMME & EXHIBITION GUIDE | POSTERS

35

Poster Supportive care, quality of life, rehabilitation

Swallowing exercises: will it really help head and neck cancer patients? W. Hashem (Egypt), R. Abdelkader, L. Abdelkader, S. Elhadary, K. Mashhour Acute and late toxicities in patients with oral cancer treated with intensity- modulated radiotherapy A. Cristaudo (Italy), S. Ursino, D. Delishaj, F. Matteucci, A. Molinari, F. Paiar Does mucosal appearance predict mucosal PRO in oropharyngeal carcinoma treated with chemo IMRT? M. Hickman (UK), T. Shantakuma, S. Meade, C. Fong, P. Sanghera, A. Hartley Head and neck cancers are associated with poor EQ-5D-related utility in France (EPICORL study) M. Schwarzinger (France), F. Huguet, S. Témam, Y. Pointreau, M. Bec, C. Even, L. Geoffrois, L. Lévy-Bachelot, S. Luchini Fentanyl Pectin Nasal Spray in head and neck cancer irradiation. First results of the PecDICO study Y. Pointreau (France), G. Bera, C. Sire, A. Ruffier, G. Janoray, G. Calais, R. Bensadoun, M. Bollet, B. Pinel, L. Martin, X. Amores Psychological profile of patients with head and neck cancer during radiotherapy: preliminary data M. Massaccesi (Italy), L. Dinapoli, A. Pesce, F. Miccichè, R. Autorino, A. Tenore, M. Balducci, V. Valentini Hypothyroidism after radiotherapy of head and neck – incidence and risk factors. U. Dworzecka (Poland), A. Wygoda, T. Rutkowski, B. Pilecki, K. Składowski A melatonin gel protects the mitochondria from radiation damage preventing mucositis G. Escames (Spain), F. Ortiz, B. Fernández-Gil, A. Guerra-Librero, Y. Shen, J. Florido, D. Acuña-Castroviejo

PO-117

PO-118

PO-119

PO-120

PO-121

PO-122

PO-123

PO-124

POSTERS | PROGRAMME & EXHIBITION GUIDE

36

Effects of melatonin oral gel to prevent radiation-induced mucositis model in rat G. Escames (Spain), C. Tarrago, F. Ortiz, B. Fernández-Gil, N. Lluch, A. Guerra-Librero, Y. Shen, J. Florido, D. Acuña-Castroviejo, R. Bosser Consenting patients for late-effects of head and neck radiotherapy: an audit of UK oncology practice J.A. Christian (UK), J. Fenwick, B. Foran Melatonin oral gel for prevention oral mucositis head and neck cancer undergoing chemo/bio radiation (MUCOMEL) A. Lozano (Spain), J. Marruecos, N. Farre, J. Giralt, R. Morera, I. Planas, M. Lanzuela, A. Escribano, L.A. Glaria, R. Mesia, J. Rubio, A. Lopez-Pousa, N. Baste, B. Castelo, B. Cirauqui, J. Martinez-Trufero, J. Ortiz, P.M. Grima, V. Valenti, C. Tarrago, R. Bosser Follow up dysphagia in head and neck cancers is related to RT dose received by swallowing structures K. George (India), R. Bhalavat, M. Chandra, L. Nellore, D. Borade, K. Kalariya, V. Pareek, Z. Moosa, N. Reddy, A. Srivastava Managing the consequences of head and neck in radiotherapy a Radiotherapy late effects clinic J. Christian (UK), E. Stones, E. Hallam Longitudinal assessment of enteral nutrition requirement in 1st line treatment of SCCHN M.N. Falewee (France), C. Michel, C. Hebert, E. Chamorey

PO-125

PO-126

PO-127

PO-128

PO-129

PO-130

Poster Minimal invasive and reconstructive surgery

Resecting the carotid artery for invasive head and neck cancer: time to reconsider its feasibility A. Jones (UK), C. Daultry, J.C. Wilton Risk of re-operation for bleeding in head and neck surgery E. Haapio (Finland), I. Kinnunen, J. Airaksinen, H. Irjala, T. Kiviniemi

PO-131

PO-132

PROGRAMME & EXHIBITION GUIDE | POSTERS

37

Occult lymphnode metastasis in early stage OPC treated with TORS without neck lymphnodes dissection D. Alterio (Italy), G. Marvaso, S.F. Zorzi, L. Preda, A. Ferrari, A. Rappa, G. Giugliano, F. Maffini, D. Sibio, C. Francia, M. Cossu Rocca, B.A. Jereczek-Fossa, M. Ansarin Retrospective analysis of treatment outcomes of sinonasal malignancies. Our 22-year experience P. Tarchini (Italy), P. Farneti, A. Bellusci, V. Sciarretta, E. Donini, G. Frezza, A. Tosoni, A. Brandes, E. Pasquini

PO-133

PO-134

Poster Epidemiology and prevention

Head and neck squamous cell carcinoma of unknown primary treated in the era of FDG-PET and IMRT M. De Ridder (The Netherlands), W.M.C. Klop, O. Hamming-Vrieze, J.P. De Boer, W. Vogel, M.W.M. Van den Brekel, A. Al-Mamgani Hospital costs associated with head and neck cancer by phase-of-care in France (EPICORL study) M. Schwarzinger (France), F. Huguet, L. Sagaon Teyssier, S. Témam, Y. Pointreau, M. Bec, C. Even, L. Lévy-Bachelot, L. Geoffrois Multivariate oral rinse models predict head and neck squamous cell carcinoma (HNSCC) M. Donovan (USA), I. Reis, K. Curtis, F. Khan, E. Franzmann

PO-135

PO-136

PO-137

Poster Salivary gland, skull base, skin and thyroid cancers

IMRT of sino-nasal cancer: improved results compared to 3D radiotherapy T. Frédéric-Moreau (France), L. Piram, J. Miroir, N. Saroul, C. Millardet, F. Kiakowski, M. Lapeyre, J. Biau Hypofractionated accelerated chemo-Tomotherapy for nasopharyngeal cancer: 2-year treatment outcomes C.T.K. Fong (UK), C.S. Boon, P. Sanghera, A. Hartley

PO-138

PO-139

POSTERS | PROGRAMME & EXHIBITION GUIDE

38

Long-term outcomes of surgery ± radiotherapy for salivary gland carcinoma at a single institution J. Williams (Australia) Adenoid cystic carcinoma of the head and neck: solid growth pattern as an adverse prognostic factor J. Fonseca (Portugal), C. Viveiros, E. Netto, S. Esteves, I. Fonseca, P. Montalvão, M. Magalhães, F. Santos A 10-year review of primary major salivary glands carcinomas H. Magalhães (Portugal), F. Pereira, C. Vieira, A. Isabel, M. Jácome, J. Dinis Salivary gland tumours: preliminary results of the Trento Protontherapy Centre I. Giacomelli (Italy), D. Scartoni, M. Cianchetti, F. Dionisi, S. Lemoine, M. Amichetti Chronic radiation-associated dysphagia after curative reirradiation. Does age affect? L. Gutierrez Bayard (Spain), M. Salas Buzón, E. Porras Alonso, S. Garduño Sánchez, M. Macias, L. De Ingunza Barón, E. González Calvo, I. Villanego Beltrán, L. Díaz Gómez, V. Díaz Díaz Definitive sequential radiotherapy in elderly patients with locally advanced oropharyngeal cancer F. De Felice (Italy), A. Galdieri, G. Abate, N. Bulzonetti, D. Musio, V. Tombolini Radiotherapy in elderly patients aged ≥ 70 years with head and neck squamous cell carcinoma E. Metcalfe (Turkey), D. Etiz, A. Ozen The ELAN program: Customized treatment of SCCHN elderly patients according to geriatric assessment J. Guigay (France), C. Ortholan, H. Le Caer, S. Renard-oldrini, X. Sun, L. Mayache-badis, L. Geoffrois, J. Fayette, C. Even, D. Vansteene, Y. Pointreau, D. Schwob, N. Vintonenko, C. Michel, J. Bourhis, A. Auperin, C. Mertens Poster Special requirements for elderly patients

PO-140

PO-141

PO-142

PO-143

PO-144

PO-145

PO-146

PO-147

PROGRAMME & EXHIBITION GUIDE | POSTERS

39

Hypofractionated radiotherapy for head and neck cancer patients unfit for standard treatment I. Desideri (Italy), P. Bonomo, C. Ciabatti, C. Muntoni, M. Lo Russo, M. Loi, D. Greto, I. Meattini, L. Livi Survival outcomes for very elderly patients after definitive radiotherapy for head and neck cancer L.M. Dixon (UK), K. Garcez, L.W. Lee, A.J. Sykes, N.J. Slevin, D.J. Thomson Age ≥70 is not an adverse prognostic factor for accelerated radiotherapy in head and neck cancer C. Terhaard (The Netherlands), N. Kasperts, H. Dehnad, E. Smid, L. Janssen, R.G. Wiggenraad, C.P.J. Raaijmakers

PO-148

PO-149

PO-150

Poster Immunodiagnosis and immunotherapy

Immunotherapy for refractory brain metastasis in cases of oropharangeal squamous cell carcinoma M. Bhandari (USA), P. Vora, A. Dugar, S. Bhati, A. DeFranco, E. Guenther

PO-151

POSTERS | PROGRAMME & EXHIBITION GUIDE

40

EXHIBITION

41

FLOORPLAN

ESTRO - European SocieTy for Radiotherapy and Oncology EHNS - European Head and Neck Society ESMO - European Society for Medical Oncology

10

30

20

20

30

CATERING

WISEPRESS MEDICAL BOOKSHOP

POSTER AREA

40

10

MERCK KGAA

50

BRISTOL-MYERS SQUIBB

100

AZANTA DANMARK A/S

160

NORGINE

170

VARIAN MEDICAL SYSTEMS INTERNATIONAL AG

180

MSD

200

ENTRANCETO EXHIBITIONHALL

REGISTRATION AREA

100

160

170

50

CATERING

180

200

40

EXHIBITION | PROGRAMME & EXHIBITION GUIDE

42

COMPANY DETAILS

AZANTA DANMARK A/S

160

on head and neck tumours. The First European Conference on Head and Neck Cancer took place in the French city of Lille in November 2001. The subsequent conferences were held bi-annually in Lille, Zagreb, Athens, Poznan´, Liverpool and Budapest. The number of participants grew each time, indicating an immense interest in the interdisciplinary ap- proach to head and neck cancer. The intent of the EHNS is to promote exchange of knowledge in all aspects of head and neck neoplastic diseases and to promote the highest standards of research, education and training, disease prevention and patient care. It is a multi-disciplinary body bringing together clinicians and other health professionals, basic scientists and patient organisations involved in any aspect of Head and Neck Oncology. Presently, 19 Europe- an countries are members of the EHNS.

Gearhalsvej 1 2500 Valby Denmark

+45 70 25 95 45 +45 70 25 95 46 info@azanta.com www.azanta.com

BRISTOL-MYERS SQUIBB 34 D. Princeton Pike Lawrence Township – NJ 08648 USA www.bms.com

100

Bristol-Myers Squibb is a global biopharmaceutical com- pany whose mission is to discover, develop and deliver in- novative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascu- lar disease, hepatitis C, HIV and rheumatoid arthritis. The Bristol-Myers Squibb Foundation’s philanthropic programs seek to promote health equity and improve the health out- comes among populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Secretary EHNS Department of Head and Neck Surgery Garbary 15, 61 – 866 Poznań Poland secretary@ehns.org www.ehns.org The European Head and Neck Society (EHNS): A True Multidisciplinary Platform for Head and Neck Oncology. The EHNS was founded in 2006 and it is the final result of a road towards a true European multidisciplinary platform EUROPEAN HEAD AND NECK SOCIETY (EHNS) 20

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)

30

Via Luigi Taddei, 4 6962 Viganello - Lugano Switzerland

+41 (0)91 973 19 00 +41 (0)91 973 19 02 esmo@esmo.org www.esmo.org

ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and infor- mation. We are committed to supporting our members to develop and advance in a fast-evolving professional envi- ronment. ESMO’s educational resources support an integrated, multi-professional approach to cancer care. We have Eu- ropean roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

PROGRAMME & EXHIBITION GUIDE | EXHIBITION

43